MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,801.77
-0.22%
NASDAQ 100
$31,160.08
-0.21%
DOW JONES
$51,180.00
-0.66%
NASDAQ Composite
$27,538.69
-0.22%
RUSSELL 2000
$2,777.00
-1.29%
CBOE VIX
$15.08
+0.47%
Sector Heatmap
Technology-0.30%
Financials-0.48%
Healthcare+1.03%
Consumer Cycl-0.32%
Consumer Staples-0.12%
Energy-0.58%
Industrials-2.18%
Materials-1.51%
Real Estate-1.29%
Utilities-0.02%
Comm Services-0.35%
PBYI — PUMA BIOTECHNOLOGY INC
NasdaqPUMA BIOTECHNOLOGY INC
$9.81
+0.31(+3.26%)
- O
- 9.45
- H
- 9.96
- L
- 9.41
- V
- 375.31K
⏱️ End-of-day dataAs of Oct 7, 2026
Chart
About PBYI
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateMar 21, 2012
Employees179
Stock ExchangeNasdaq
Ticker SymbolPBYI
Key Financial Statistics
| Market Cap | $490.91M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $4.58 - $10.10 |
| 52-Week Avg Volume | 374.9K |
| VWAP | $9.81 |
| Transactions | 7,037 |
| Total Recorded Bars | 3,635 days |